skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival

Translational oncology, 2020-10, Vol.13 (10), p.100826-100826, Article 100826 [Peer Reviewed Journal]

2020 The Authors ;Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved. ;2020 The Authors 2020 ;ISSN: 1936-5233 ;EISSN: 1936-5233 ;DOI: 10.1016/j.tranon.2020.100826 ;PMID: 32659740

Full text available

Citations Cited by
  • Title:
    Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival
  • Author: Higuchi, Takashi ; Sugisawa, Norihiko ; Park, Jun Ho ; Sun, Yu ; Zhu, Guangwei ; Yamamoto, Norio ; Hayashi, Katsuhiro ; Kimura, Hiroaki ; Miwa, Shinji ; Igarashi, Kentaro ; Bouvet, Michael ; Singh, Shree Ram ; Tsuchiya, Hiroyuki ; Hoffman, Robert M.
  • Subjects: Bone metastasis ; Non-small-cell lung carcinoma ; Original article ; Orthotopic mouse model ; Osimertinib
  • Is Part Of: Translational oncology, 2020-10, Vol.13 (10), p.100826-100826, Article 100826
  • Description: Bone is one of the most frequent metastatic sites in non-small cell lung cancer (NSCLC). Osimertinib, with and without bevacizumab (BV), has been investigated on advanced NSCLC patients. However, the efficacy of those drugs on bone metastasis of NSCLC has not been investigated. The human NSCLC cell line H1975, expressing red fluorescent protein (H1975-RFP), was orthotopically injected to the tibia of nude mice. The established mouse models were randomized into four treatment groups of nine mice: Control; BV alone; osimertinib alone; osimertinib and BV combination. The tumors were observed by non-invasive fluorescence imaging. Osimertinib, with or without BV, caused tumor regression, increased mouse survival, and bone remodeling in the bone metastasis models. These results suggest that osimertinib is a promising clinical option for NSCLS patients with bone metastasis. •Bone is a frequent metastatic site in non-small cell lung cancer (NSCLC).•Established imageable orthotopic xenograft mouse model for NSCLC•Osimertinib and osimertinib + BV regressed the NSCLC bone metastasis.•Osimertinib and osimertinib + BV increased mouse survival and bone remodeling.•Osimertinib is a promising clinical option for NSCLS patients with bone metastasis.
  • Publisher: United States: Elsevier Inc
  • Language: English
  • Identifier: ISSN: 1936-5233
    EISSN: 1936-5233
    DOI: 10.1016/j.tranon.2020.100826
    PMID: 32659740
  • Source: Open Access: PubMed Central
    Geneva Foundation Free Medical Journals at publisher websites
    Directory of Open Access Journals
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait